Public Sector Pension Investment Board Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Public Sector Pension Investment Board bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 283,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,619,000. Public Sector Pension Investment Board owned 0.18% of TG Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Lazard Asset Management LLC purchased a new stake in TG Therapeutics in the 1st quarter worth about $91,000. Price T Rowe Associates Inc. MD boosted its holdings in TG Therapeutics by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 5,015 shares during the period. Cetera Advisors LLC bought a new position in TG Therapeutics in the 1st quarter valued at $622,000. DekaBank Deutsche Girozentrale purchased a new stake in TG Therapeutics in the first quarter worth $58,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of TG Therapeutics during the second quarter worth $8,698,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 0.6 %

Shares of NASDAQ:TGTX opened at $34.80 on Friday. The company has a market capitalization of $5.42 billion, a PE ratio of -348.00 and a beta of 2.19. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $12.37 and a 12-month high of $36.84. The business’s fifty day simple moving average is $26.59 and its 200-day simple moving average is $22.26.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on TGTX shares. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright increased their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is currently owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.